These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1610 related items for PubMed ID: 28923865

  • 1. In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
    Goodlet KJ, Nicolau DP, Nailor MD.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D, Pfaller MA, Castanheira M, Flamm RK.
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [Abstract] [Full Text] [Related]

  • 3. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [Abstract] [Full Text] [Related]

  • 4. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [Abstract] [Full Text] [Related]

  • 5. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 6. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA, Bassetti M, Duncan LR, Castanheira M.
    J Antimicrob Chemother; 2017 May 01; 72(5):1386-1395. PubMed ID: 28165526
    [Abstract] [Full Text] [Related]

  • 7. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M, Sutherland C, Nicolau DP.
    Antimicrob Agents Chemother; 2017 Oct 01; 61(10):. PubMed ID: 28739780
    [Abstract] [Full Text] [Related]

  • 8. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A, Tan E, McCarthy KL, Paterson DL.
    Pathology; 2018 Dec 01; 50(7):748-752. PubMed ID: 30392710
    [Abstract] [Full Text] [Related]

  • 9. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
    Shortridge D, Castanheira M, Pfaller MA, Flamm RK.
    Antimicrob Agents Chemother; 2017 Jul 01; 61(7):. PubMed ID: 28483953
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH.
    Antimicrob Agents Chemother; 2016 May 01; 60(5):3227-31. PubMed ID: 26976862
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Oct 01; 69(10):2713-22. PubMed ID: 24917579
    [Abstract] [Full Text] [Related]

  • 12. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Shortridge D, Castanheira M.
    Int J Antimicrob Agents; 2023 Apr 01; 61(4):106744. PubMed ID: 36738849
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I, Kucukercan M, Ceran N.
    Chemotherapy; 2003 Dec 01; 49(6):294-7. PubMed ID: 14671429
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC, Hortaç E, Koçak AA, Demirkaya MH, Yayla B, Güçlü AÜ, Başustaoğlu A.
    J Glob Antimicrob Resist; 2020 Mar 01; 20():334-338. PubMed ID: 31568882
    [Abstract] [Full Text] [Related]

  • 15. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
    Pfaller MA, Shortridge D, Harris KA, Garrison MW, DeRyke CA, DePestel DD, Moise PA, Sader HS.
    Int J Infect Dis; 2021 Nov 01; 112():321-326. PubMed ID: 34597763
    [Abstract] [Full Text] [Related]

  • 16. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A.
    Antimicrob Agents Chemother; 2017 Nov 01; 61(11):. PubMed ID: 28874376
    [Abstract] [Full Text] [Related]

  • 17. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF.
    J Med Microbiol; 2022 Apr 01; 71(4):. PubMed ID: 35451945
    [Abstract] [Full Text] [Related]

  • 18. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H, Körber-Irrgang B, Kresken M, German Ceftolozane/Tazobactam Study Group.
    Int J Antimicrob Agents; 2018 Feb 01; 51(2):227-234. PubMed ID: 28705666
    [Abstract] [Full Text] [Related]

  • 19. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M.
    J Glob Antimicrob Resist; 2017 Sep 01; 10():186-194. PubMed ID: 28735046
    [Abstract] [Full Text] [Related]

  • 20. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Jun 01; 43(6):533-9. PubMed ID: 24856078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.